H.R. 5882 · 116th Congress
GENE Therapy Payment Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SchraderSponsor6 cosponsors · 2 D, 4 R
6 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act
What it does: CRS summary · Introduced in House · Feb 12, 2020
Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act
This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: GENE Therapy Payment Act
Also known as: Generating Effective and Novel Evidence for Therapy Payment Act
Latest action (Feb 12, 2020): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Feb 12, 2020
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.